Walleye Capital
OTLK icon

Walleye Capital’s Outlook Therapeutics OTLK Stock Holding History

Walleye Capital’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-41,426
Closed -$306K – 5725
2024
Q2 		$306K Buy
41,426
+7,921
+24% +$63.6K ﹤0.01% 3964
2024
Q1 		$400K Buy
+33,505
New +$271K ﹤0.01% 3401
2021
Q4 		– Sell
-2,378
Closed -$103 – 2257
2021
Q3 		$103 Buy
2,378
+928
+64% +$44.8K ﹤0.01% 1332
2021
Q2 		$72 Buy
+1,450
New +$67.3K ﹤0.01% 1201

Other funds holding OTLK

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Walleye Capital's OTLK Position: Q3 2024 in Review

Walleye Capital sold out of Outlook Therapeutics (OTLK) in Q3 2024, closing a stake of 41,426 shares — an estimated $306K sold.

Walleye Capital first reported a position in OTLK in Q2 2021 and held it in 4 quarters. The position peaked at $400K in Q1 2024. 66 funds tracked by Wall St. Rank hold OTLK as of Q3 2024.

  • Walleye Capital reported no remaining Outlook Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Walleye Capital sold 41,426 Outlook Therapeutics shares in Q3 2024, an estimated $306K.
  • Walleye Capital first reported a position in Outlook Therapeutics in Q2 2021 and held it in 4 quarters.
  • Walleye Capital's Outlook Therapeutics position peaked at $400K in Q1 2024.
  • 66 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.